6978 Stock Overview
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Immunotech Biopharm Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.31 |
| 52 Week High | HK$5.00 |
| 52 Week Low | HK$3.02 |
| Beta | 0.85 |
| 1 Month Change | -11.26% |
| 3 Month Change | -17.46% |
| 1 Year Change | -10.78% |
| 3 Year Change | -80.89% |
| 5 Year Change | n/a |
| Change since IPO | -78.62% |
Recent News & Updates
Shareholder Returns
| 6978 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.1% | 8.1% | 3.5% |
| 1Y | -10.8% | -40.2% | -9.9% |
Return vs Industry: 6978 exceeded the Hong Kong Biotechs industry which returned -40.2% over the past year.
Return vs Market: 6978 matched the Hong Kong Market which returned -9.9% over the past year.
Price Volatility
| 6978 volatility | |
|---|---|
| 6978 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 6978's share price has been volatile over the past 3 months.
Volatility Over Time: 6978's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 211 | Yu Wang | www.eaal.net |
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer.
Immunotech Biopharm Ltd Fundamentals Summary
| 6978 fundamental statistics | |
|---|---|
| Market cap | HK$1.70b |
| Earnings (TTM) | -HK$361.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs 6978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6978 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥334.82m |
| Earnings | -CN¥334.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 191.3% |
How did 6978 perform over the long term?
See historical performance and comparison